Analysis of Response of Subjects With Atopic Dermatitis or Psoriasis to Oral Vitamin D3
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This study will examine whether administration of oral Vitamin D3 given over 21 days will
change the antimicrobial peptide expression in the skin or saliva of subjects with Atopic
Dermatitis (AD). This study will help researchers determine if the lack of the expression of
antimicrobial peptides in individuals with AD plays a role in the susceptibility to eczema
vaccinatum (EV).
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
Consortium of Food Allergy Research
Treatments:
Anti-Infective Agents Cholecalciferol Ergocalciferols Vitamin D Vitamins